Claris confirms break-up with Pfizer
This article was originally published in Scrip
Claris Lifesciences has confirmed that its supply agreement with Pfizer has been terminated and it will pursue selling products on its own in the US. Scrip had on 22 August reported that the alliance had been called off and that Pfizer had 'no current plans' to source 'any products' from Claris (scripintelligence.com 22 August 2012).
You may also be interested in...
Years after a scathing Indian parliamentary report flagged concerns around regulatory lapses for drug approvals, an expert panel has endorsed the continued marketing of ambrisentan and everolimus in the country. But dronedarone, also featured in the report, is no longer sold by Sanofi in India.
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.